Long-term follow-up of CAR-T therapy for B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study follows patients who already received an anti-CD19 CAR-T cell treatment in a previous study to check long-term safety and how well it keeps working. It's for people with B-cell blood cancers (like lymphoma) and involves extra monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous study of this CAR-T therapy (HemC101-01-01).
- If you could become pregnant, you need a negative pregnancy test before joining.
- You cannot have an uncontrolled, life-threatening infection. A simple urinary tract infection is okay.
- You must not have used certain immune-suppressing treatments recently, like steroids, chemotherapy, or biologic medicines from mice.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study follows children and young adults who received CAR T cell therapy to understand any long-term side effects that may appear months to years later. By joining, you help researchers learn how to better care for patients after this treatment.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
Hear when a new Non-Hodgkin Lymphoma, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.